SCHEMBL31161591

SCHEMBL31161591

Cc1nc(C#N)cc(Br)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GLA P06280 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MBOAT4 Q96T53 1/20 0.35
EGLN2 Q96KS0 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
THRB P10828 1/20 0.31
ALDH1A1 P00352 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
RORC P51449 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11942292 0.80 MEN1 (0.38) MEN1KMT2AGLATSHRHTT
SCHEMBL11986178 0.80 LMNA (0.34) MEN1KMT2AHTTKDM4EMBOAT4
SCHEMBL29331580 0.77 ALDH1A1 (0.35) MEN1KMT2AKDM4EMBOAT4CYP1A2
SCHEMBL30938639 0.77 ALDH1A1 (0.35) MEN1KMT2AKDM4EMBOAT4CYP1A2
SCHEMBL25239817 0.77 MBOAT4 (0.37) MEN1KMT2AHTTKDM4EMBOAT4
SCHEMBL30478351 0.77 MBOAT4 (0.37) MEN1KMT2AHTTKDM4EMBOAT4
SCHEMBL14853157 0.72 KDM4E (0.33) MEN1KMT2AKDM4EMBOAT4EGLN2
SCHEMBL11986175 0.72 ALDH1A1 (0.38) MEN1KMT2AGLATSHRHTT
SCHEMBL32684056 0.69 NOS2 (0.37) HTTCYP1A2CYP2C9CYP2C19NPSR1
SCHEMBL149575 0.69 EGLN2 (0.39) KMT2AMBOAT4EGLN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 MEN1 4258/4885KMT2A 242/4885GLA 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.